healio.com
VIDEO: Response predictors, head-to-head trials still needed in Crohn’s research
People with Crohn’s disease and their clinicians need ways to predict which medication will work best and to know how different drugs compare. Better predictors and head-to-head trials could reduce trial-and-error treatment, delays in effective care, and steroid dependence.
Clinicians treating IBD, researchers working on predictive biomarkers or comparative trials, patients considering biologic or advanced therapies, and caregivers involved in treatment decisions.
What To Know
Researchers and clinicians want better tools to choose the right therapy for each person with Crohn’s disease. This Healio video highlights two key gaps: lack of validated predictors (biomarkers) to tell which patient will respond to which drug, and a shortage of head-to-head trials comparing available medicines.
The speaker explains that although many effective medications now exist, clinicians often must guess which patient will benefit from which drug because we don’t yet have reliable blood, stool, or biopsy tests to predict response. That makes the choice of first therapy especially important, since initial treatment is often the most likely to work.
The video also emphasizes the need for more head-to-head clinical trials to compare drugs and inform the optimal order of therapies. Practical perspective: This is a commentary-style video, not a research report of new study results.
It summarizes expert views about gaps in Crohn’s research and care—predictive biomarkers and comparative trials—rather than presenting new data or specific test options. Further reading: Clinical trial registries and guideline updates are the places to watch for future head-to-head trial results or validated predictive tests.
This is a short expert interview (video transcript) outlining unmet needs rather than reporting new study data. No specific biomarkers, drugs, or trial results are described; it’s a call for more research and comparative trials.
